Nusinersen
Last Updated: 11/08/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 1127 publications
Machine learning predicts treatment response to nusinersen in non-sitter spinal muscular atrophy (SMA).
Journal: Journal of neuromuscular diseases
Published: October 20, 2026
Neurofilaments in cerebrospinal fluid and/or serum as a possible biomarker of pediatric spinal muscular atrophy.
Journal: Journal of neuromuscular diseases
Published: October 17, 2026
Development of Antisense Gapmers for the Treatment of Huntington's Disease.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: September 30, 2026
Spinal muscular atrophy as a blueprint for precision therapy in neuromuscular disease.
Journal: Expert reviews in molecular medicine
Published: September 23, 2026
Clinical analysis of nusinersen for spinal muscular atrophy types 2 and 3 in children
Journal: Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics
Published: September 17, 2026
Real-world pharmacoclinical implementation of risdiplam under a national SMA protocol: A hospital pharmacy registry-based case series.
Journal: Pakistan journal of pharmaceutical sciences
Published: August 22, 2026
Nusinersen for type-III spinal muscular atrophy: a 12-month retrospective study in a Brazilian cohort.
Journal: Arquivos de neuro-psiquiatria
Published: July 17, 2026
Managing nusinersen therapy during pregnancy in spinal muscular atrophy type 3.
Journal: BMJ case reports
Published: July 15, 2026
The role of vascular pathology in SMA: implications for pathogenesis and treatment.
Journal: Frontiers in cellular neuroscience
Published: July 09, 2026
Last Updated: 11/08/2026